<DOC>
	<DOCNO>NCT02387853</DOCNO>
	<brief_summary>An international , multi-centre , prospective , open-label , non-controlled , single-group , 4-week trial adolescent subject plaque psoriasis .</brief_summary>
	<brief_title>Safety Efficacy Once Daily Topical Treatment With LEO 90100 Aerosol Foam Adolescent Subjects With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion Criteria ( subject ) Psoriasis vulgaris trunk and/or limbs affect least 2 % BSA . Psoriasis vulgaris scalp affect least 10 % total scalp area . A total psoriatic involvement trunk , limbs scalp exceed 30 % BSA . PGA score least mild trunk and/or limbs SV1 , SV2 V1 . PGA score least mild scalp SV1 , SV2 V1 . A serum albumincorrected calcium upper reference limit SV2 . Inclusion Criteria ( subject perform HPA axis assessment ) Psoriasis vulgaris trunk and/or limbs affect least 10 % BSA . Psoriasis vulgaris scalp affect least 20 % total scalp area . PGA score least moderate trunk limb SV1 , SV2 V1 . PGA score least moderate scalp SV1 , SV2 V1 . Normal HPA axis function SV2 ( serum cortisol concentration 5 mcg/dl ACTH challenge serum cortisol concentration 18 mcg/dl 30 minute ACTH challenge ) . Exclusion Criteria ( subject ) : A history hypersensitivity component LEO 90100 . Systemic treatment biological therapy ( market market ) , possible effect scalp and/or body psoriasis within follow time period prior V1 trial : 1. etanercept within 4 week prior V1 2. adalimumab , infliximab within 2 month prior V1 3. ustekinumab within 4 month prior V1 4. experimental product within 4 weeks/5 halflives ( whichever longer ) prior V1 Systemic treatment therapy biologicals , possible effect scalp and/or body psoriasis ( e.g . methotrexate , retinoids , immunosuppressant ) within 4 week prior V1 trial . PUVA therapy within 4 week prior V1 . UVB therapy within 2 week prior V1 trial . Exclusion Criteria ( subject perform HPA axis assessment ) : A history serious allergy , allergic asthma serious allergic skin rash . Known suspected hypersensitivity component CORTROSYNÂ® ( include ACTH/cosyntropin/tetracosactide ) Systemic treatment corticosteroid ( include inhale nasal steroid ) within 12 week prior SV2 trial . Oestrogen therapy ( include contraceptive ) medication know affect cortisol level HPA axis integrity within 4 week prior SV2 trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>